The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer

Randomized phase II study comparing dose-escalated weekly paclitaxel (wPTX) versus standard-dose wPTX for patients with previously treated advanced gastric cancer (AGC).

(2017) Daisuke Takahari et al.   JOURNAL OF CLINICAL ONCOLOGY

S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial)

(2014) M. Yoshida et al.   ANNALS OF ONCOLOGY

A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study

(2014) Hirofumi Yasui et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

(2014) Volker Heinemann et al.   LANCET ONCOLOGY

Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial

(2013) Yasuhide Yamada et al.   LANCET ONCOLOGY

Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer

(2012) Yoshito Komatsu et al.   ACTA ONCOLOGICA

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

(2012) H. J. Schmoll et al.   ANNALS OF ONCOLOGY

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial

(2012) Yong Sang Hong et al.   LANCET ONCOLOGY

Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement

(2011) Vicki C Tse et al.   BMC CANCER

Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer

(2011) Yasuhide Yamada et al.   INVESTIGATIONAL NEW DRUGS

Cost-Minimisation Analysis in First-Line Treatment of Metastatic Colorectal Cancer in France: XELOX versus FOLFOX-6

(2011) G. Perrocheau et al.   ONCOLOGY

Phase II Study of Combined Treatment with Irinotecan and S-1 (IRIS) in Patients with Inoperable or Recurrent Advanced Colorectal Cancer (HGCSG0302)

(2011) Yoshito Komatsu et al.   ONCOLOGY

Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)

(2010) Kei Muro et al.   LANCET ONCOLOGY

Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer

(2009) D. Y. Zang et al.   ANNALS OF ONCOLOGY

Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials

(2009) T Shiroiwa et al.   BRITISH JOURNAL OF CANCER

XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis

(2009) Nikos Maniadakis et al.   CURRENT MEDICAL RESEARCH AND OPINION

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

(2009) Jolien Tol et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer

(2008) Y Yamada et al.   BRITISH JOURNAL OF CANCER

S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study

(2008) Junji Furuse et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Can Inhibiting Dihydropyrimidine Dehydrogenase Limit Hand-Foot Syndrome Caused by Fluoropyrimidines?

(2008) J. L. Yen-Revollo et al.   CLINICAL CANCER RESEARCH

Development History and Concept of an Oral Anticancer Agent S-1 (TS-1(R)): Its Clinical Usefulness and Future Vistas

(2008) T. Shirasaka   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

(2008) Jim Cassidy et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

(2008) Leonard B. Saltz et al.   JOURNAL OF CLINICAL ONCOLOGY